--> See all Alzheimer names under pressure, ROG Underperforming
Biogen Alzheimer's Drug Fails to Deliver on Key Lower Dose
2015-07-22 12:49:42.12 GMT
BI BIOT GLOB SBKEYS
The 6-milligram dose of Biogen's Alzheimer's drug aducanumab
(BIIB037) failed to show statistically significant benefit in
cognitive function in its PRIME study at 54 weeks, tempering
expectations for its potential. The 10-mg dose showed
significant improvement in 1Q, but a high incidence of
toxicities such as brain swelling (ARIA) caused concern. The
6-mg dose was viewed potentially as a trade-off in risk, yet
results released July 22 call into question whether it will have
a sufficient benefit in a larger study.
|0|0|553534|200960877|NOT_APPLICABLE|NOT_APPLICABLE|
This research note has been published by Bloomberg Intelligence.
For more information, see BI <GO>
-0- Jul/22/2015 12:49 GMT
2015-07-22 12:49:42.12 GMT
BI BIOT GLOB SBKEYS
The 6-milligram dose of Biogen's Alzheimer's drug aducanumab
(BIIB037) failed to show statistically significant benefit in
cognitive function in its PRIME study at 54 weeks, tempering
expectations for its potential. The 10-mg dose showed
significant improvement in 1Q, but a high incidence of
toxicities such as brain swelling (ARIA) caused concern. The
6-mg dose was viewed potentially as a trade-off in risk, yet
results released July 22 call into question whether it will have
a sufficient benefit in a larger study.
|0|0|553534|200960877|NOT_APPLICABLE|NOT_APPLICABLE|
This research note has been published by Bloomberg Intelligence.
For more information, see BI <GO>
-0- Jul/22/2015 12:49 GMT